OBJECTIVESTo develop a host-vector system for heterologous protein co-expression and purification in the Trichoderma reesei (teleomorph Hypocrea jecorina) industrial strain RUT-C30.RESULTSThe co-expression and purification system is based on: (i) an efficient and reliable selectable marker using bar (phosphinothricin acetyltransferase gene); (ii) a compact hygromycin B resistance marker; and (iii) a versatile integration plasmid for gene expression and knockout. Fluorescent protein genes were introduced into T. reesei and the corresponding proteins were purified from fermentation broth. The host-vector system was used in a proof-of-principle approach to achieve the co-expression of an alkaline endoglucanase and an alkaline cellobiohydrolase.CONCLUSIONSThis protocol can be used at an industrial scale to produce large amounts of proteins in T. reesei.

Yaowu Shengwu Jishu

Study on stable interferon liquid formulation

Author: Deng, Jie ; Tian, Li ; Zhang, Lei ; Cao, Lin

A stable interferon liquid formulation was made by using bionics principle.Hydroxyethyl starch-40, citrate buffer, etc., were used to stabilize interferon.The formulation was free of human serum albumin or preservative, and no inert gas protection was needed.The bioactivity of interferon α-2b in the formulation could be kept stable at 8° for 36 mo, and good tolerance in temperature, vibration, illumination, and freeing-thawing was shown.The acute toxicity experiments and topical irritative reaction experiments showed that the stable interferon liquid formulation accorded with the pharmaceutics regulations.The stable interferon solution had activity of anti-SARS, EC₅₀ = 12 IU/mL, TI >850.

News (Medical) associated with Tianjin Hualida Biotechnology Co. Ltd.

29 Mar 2006

·www.biospace.com

Teva Pharmaceutical Industries Limited Expands Presence In China; Increases Equity Stake In Hualida Biotechnology To 60%

JERUSALEM--(BUSINESS WIRE)--March 30, 2006--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has increased its equity ownership in Tianjin Hualida Biotechnology Co., Ltd. in Tianjin, from 45% to 60%.

100 Deals associated with Tianjin Hualida Biotechnology Co. Ltd.

100 Translational Medicine associated with Tianjin Hualida Biotechnology Co. Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 19 Jul 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Tianjin Hualida Biotechnology Co. Ltd.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 19 Jul 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing